The Efficacy of Platelets Rich Plasma for Ovarian Rejuvenation

May 3, 2023 updated by: Yousif Abdulraheem, Al-Kindy College of Medicine

The Efficacy of Platelets Rich Plasma (PRP) for Ovarian Rejuvenation

In recent years, an increased approach has appeared in the use of autologous blood products to assist tissue and organ healing. Application of platelet rich plasma (PRP) has emerged as a potential solution for infertile women with poor ovarian reserve in reproductive specialty.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Quantitative and qualitative functional improvement of ovarian function has been reported in several studies after using autologous PRP in a reproductive field. Ovarian rejuvenation, stimulating the ovaries to produce new eggs after injecting PRP, can offer hope for renewed fertility to women with poor reserve volume, advanced maternal age, or either naturally occurring or premature menopause. But, these encouraging results should be supported by several new studies.

This study aimed to estimate the efficacy of trans-vaginal ovarian injection with PRP in rejuvenates ovaries in woman with poor ovarian reserve, and to assess any association of some women variables (age, menstrual status, parity, BMI) as predicting factors in success of ovarian injection with PRP.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
      • Baghdad, Iraq
        • High Institute for Infertility Diagnosis and Assisted Reproductive Technologies

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 49 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Menopause or peri-menopause under the age of 50.
  2. Premature ovarian insufficiency which is ovarian failure before the age of 40.
  3. Woman with primary ovarian failure of any cause.

Exclusion Criteria:

  1. A previous injection with any medication, plasma, or PRP
  2. Invisible or difficult access ovaries.
  3. Medical disease or unfit for anesthesia patient.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Poor ovarian reserve
Infertile women with poor ovarian reserve
Other: Autologous PRP preparation
For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
Other Names:
  • Plasma Rich Platelets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Follicle-stimulating hormone (FSH) concentration
Time Frame: 4 weeks
Before after intervention measurement
4 weeks
Anti-Müllerian hormone (AMH) concentration
Time Frame: 4 weeks
Before after intervention measurement
4 weeks
Antral follicles numbers
Time Frame: 4 weeks
Before after intervention measurement
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Kindy College of Medicine

Collaborators

High Institute for Infertility Diagnosis and Assisted Reproductive Technologies

Investigators

  • Study Director: Thuraya H Abdulla, Professor, Arab Board for Medical Specializations

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • A

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 20, 2018

Primary Completion (Actual)

May 31, 2019

Study Completion (Actual)

May 31, 2019

Study Registration Dates

First Submitted

May 6, 2019

First Submitted That Met QC Criteria

May 9, 2019

First Posted (Actual)

May 13, 2019

Study Record Updates

Last Update Posted (Estimate)

May 4, 2023

Last Update Submitted That Met QC Criteria

May 3, 2023

Last Verified

October 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 12 Al-KindyCM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

All data will be managed confidentially

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility, Female

Clinical Trials on Autologous PRP preparation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe